[PERSON]
Frederick Vogt
Featured in 1 tracked story · first seen
Situations
Iovance Biotherapeutics market performance
2 clusters · 6 sources · last updated
Latest: Iovance Biotherapeutics shares surge on raised 2026 revenue forecast
Iovance Biotherapeutics experienced significant stock growth driven by positive analyst sentiment and improved financial outlooks. Initially, shares reached a 52-week high following a Goldman Sachs upgrade to a ‘buy’ rat